49 results on '"Longinetti, Elisa"'
Search Results
2. COVID-19–Related Enhancement for the COMBAT-MS Study
Catalog
Books, media, physical & digital resources
3. Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study
4. Heart rate, intelligence in adolescence, and Parkinson’s disease later in life
5. Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic
6. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
7. Original research: Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.
8. History of violence/maltreatment and psychogenic non-epileptic seizures
9. Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy
10. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
11. Utilization of social media and web forums by HIV patients - A cross-sectional study on adherence and reported anxiety level
12. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
13. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature
14. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis diseasemodulating therapy.
15. Correlates of mobile phone use in HIV care: Results from a cross-sectional study in South Africa
16. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
17. COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
18. COVID-19 clinical outcomes and DMT of MS patients and population-based controls
19. Mortality among family members of patients with amyotrophic lateral sclerosis : a Swedish register-based study
20. Geographical clusters of amyotrophic lateral sclerosis and the Bradford Hill criteria
21. sj-docx-5-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies
22. sj-docx-2-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies
23. sj-docx-3-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies
24. sj-docx-1-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies
25. sj-docx-4-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies
26. Mortality among family members of patients with amyotrophic lateral sclerosis – a Swedish register-based study
27. Mortality among family members of patients with amyotrophic lateral sclerosis – a Swedish register-based study
28. Risk of depression in multiple sclerosis across disease-modifying therapies
29. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study
30. Associations between autoimmune diseases and amyotrophic lateral sclerosis : a register-based study
31. Geographical clusters of amyotrophic lateral sclerosis and the Bradford Hill criteria.
32. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study
33. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study.
34. Risk of depression in multiple sclerosis across disease-modifying therapies.
35. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study
36. Amyotrophic lateral sclerosis and multiple sclerosis associated neuroinflammation : nationwide epidemiological studies on etiology, comorbidities, and treatment
37. Symptomatic drug therapy impact on Amyotrophic Lateral Sclerosis survival
38. The Swedish motor neuron disease quality registry
39. The Swedish motor neuron disease quality registry
40. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis
41. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis
42. Physical and cognitive fitness in young adulthood and risk of amyotrophic lateral sclerosis at early age
43. Gender Perspective of Risk Factors Associated with Disclosure of HIV Status, a Cross-Sectional Study in Soweto, South Africa
44. Predictors of Patient-Reported Fatigue Symptom Severity in a Nationwide Multiple Sclerosis Cohort
45. Symptomatic drug therapy impact on Amyotrophic Lateral Sclerosis survival
46. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
47. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.
48. Mortality among family members of patients with amyotrophic lateral sclerosis - a Swedish register-based study.
49. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.